Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study (PEACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03004755
Recruitment Status : Recruiting
First Posted : December 29, 2016
Last Update Posted : February 23, 2022
Sponsor:
Collaborator:
Cancer Research UK
Information provided by (Responsible Party):
University College, London

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Historically, cancer research has been limited by sample acquisition in late stage disease, often restricted to single sites of disease with limited parallel clinical data collection in terms of prior therapy exposure. The PEACE study is intended to facilitate tissue donation from multiple tumour sites in the post-mortem setting and enable future research using samples collected at post-mortem within different disciplines related to cancer research.

Condition or disease Intervention/treatment
Solid Tumor, Adult Cancer Other: Tissue Harvest

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
Study Start Date : March 2014
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2023
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Perform 500 post mortems [ Time Frame: 5 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Solid tumour malignancy with metastatic disease
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Confirmed diagnosis of any form of solid malignancy with metastatic disease (where the site of origin is known or unknown), with the exception of primary brain tumour in which there may not be evidence of metastatic disease
  • Oral and written informed consent from patient to enter the study and to undergo tumour harvesting after death or informed consent from a person in a qualifying relationship after the patient has died.

Exclusion Criteria:

  • Medical or psychiatric condition that would preclude informed consent
  • History of intravenous drug abuse within the last 5 years
  • History of known high-risk infections (e.g. HIV/AIDS-positive, hepatitis B/C, tuberculosis and Creutzfeldt-Jacob disease).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03004755


Contacts
Layout table for location contacts
Contact: Abby Sharp 02076799688 ctc.peace@ucl.ac.uk

Locations
Layout table for location information
United Kingdom
Heart of England NHS Foundation Trust Recruiting
Birmingham, United Kingdom
Cambridge University NHS Trust Recruiting
Cambridge, United Kingdom
Greater Glasgow Health Board Recruiting
Glasgow, United Kingdom
University Hospitals of Leicester NHS Trust Recruiting
Leicester, United Kingdom
Guy's and St Thomas NHS Foundation Trust Recruiting
London, United Kingdom
The Royal Marsden NHS Foundation Trust Recruiting
London, United Kingdom
University College London Hospitals NHS Foundation Trust Recruiting
London, United Kingdom
The Christie NHS Foundation Trust Recruiting
Manchester, United Kingdom
Oxford University Hospitals NHS Trust Not yet recruiting
Oxford, United Kingdom
Sponsors and Collaborators
University College, London
Cancer Research UK
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Gronroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium; Swanton C. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum In: Nature. 2017 Dec 20;:

Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT03004755    
Other Study ID Numbers: UCL/13/0165
First Posted: December 29, 2016    Key Record Dates
Last Update Posted: February 23, 2022
Last Verified: February 2022